Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.
Yao
Song
S
Department of Cancer and Prevention and Control, Roswell Park Cancer Institute, Elm & Carlton Sts, Buffalo, NY 14263, USA. Song.Yao@roswellpark.org
Barlow
William E
WE
Albain
Kathy S
KS
Choi
Ji-Yeob
JY
Zhao
Hua
H
Livingston
Robert B
RB
Davis
Warren
W
Rae
James M
JM
Yeh
I-Tien
IT
Hutchins
Laura F
LF
Ravdin
Peter M
PM
Martino
Silvana
S
Lyss
Alan P
AP
Osborne
C Kent
CK
Abeloff
Martin D
MD
Hortobagyi
Gabriel N
GN
Hayes
Daniel F
DF
Ambrosone
Christine B
CB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics* / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D016015:Logistic Models; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000201:enzymology / Q000235:genetics; D016017:Odds Ratio; D010641:Phenotype; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D015206:Southwestern United States; D013482:Superoxide Dismutase / Q000235:genetics* / Q000378:metabolism; D013629:Tamoxifen / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D000099156:Superoxide Dismutase 2
D003520:Cyclophosphamide; D004317:Doxorubicin; D005472:Fluorouracil; D008727:Methotrexate; D013482:Superoxide Dismutase; D013629:Tamoxifen; D000099156:Superoxide Dismutase 2